Searchable abstracts of presentations at key conferences in endocrinology

ea0026p289 | Pituitary | ECE2011

ACTH-secreting pituitary adenomas express higher SSTR5 than SSTR2 protein levels by immunohistochenistry using new monoclonal antibodies against SST-binding domains

Rossi V , Bellastella G , Staibano S , Ilardi G , Del Basso De Caro M L , Cavallo L , Cappabianca P , Abbondanza C , Colao A , Bellastella A , Sinisi A A

Pasireotide (SOM230), a somatostatin (SST) analogue targeting multiple SST receptors, is effective in reducing urinary free cortisol in patients with Cushing disease (CD), due to inoperable or recurrent ACTH secreting pituitary adenomas. The efficacy of SOM230 seems to be dependent on the presence of appropriate SSTRs, mainly SSTR2 and 5, on the membrane of tumor cells. Polyclonal antibodies available up to now recognizing cellular intracellular sites of receptors and their re...

ea0029p1419 | Pituitary Clinical | ICEECE2012

Immunohistochemical detection of sstr2 and 5 ligand binding domains in 110 pituitary tumors

Rossi V. , Ilardi G. , Massimo M. , Bellastella G. , Visconti D. , Staibano S. , Del Basso De Caro M. , Abbondanza C. , Cavallo L. , De Bellis A. , Cappabianca P. , Colao A. , De Rosa G. , Bellastella A. , Sinisi A.

Classical somatostatin analogues (SST-A), such as octreotide and lanreotide, bind mainly SSTR2 whilst the multiligand pasireotide binds with the highest affinity SSTR5. The selective immunodetection of ligand binding domain (LBD) of SSTR subtypes with specific monoclonal antibodies may be useful to explain the potential efficacy of different SSTA on pituitary tumours growth and/or secretory activity.Patients and Methods: We applied new monoclonal antibod...